IGC Pharma, Inc. — fact timeline

IGC Pharma, Inc. entered into Amendment to Master Loan and Security Agreement with O-Bank Co., Ltd. valued at Facility limit of $12,000,000; facility fee increased from $48,000 to $60,000 (effective 2026-06-05).

“On June 5, 2026, IGC Pharma, Inc. (“IGC” or the “Company”) entered into an amendment to extend its existing Master Loan and Security Agreement together with the General Banking Facility Letter (collectively, the “Loan Agreement”) with O-Bank Co., Ltd., a banking corporation incorporated under the laws of Taiwan, as lender (the “Lender”). The Loan Agreement continues the facility arrangement previously set forth in the General Banking Facility Letter dated June 24, 2025. The facility provides for a maximum aggregate limit of $12,000,000. The material terms of the facility remain substantially unchanged from the 2025 facility letter, except that the facility fee has increased from $48,000 to $60,000.”

IGC Pharma, Inc. issued common stock to the holders of the Notes, including FirstFire Global Opportunities Fund, LLC and Vanquish Funding Group Inc..

“The information set forth under Item 1.01 above is incorporated by reference into this Item 3.02. Any Conversion Shares issuable upon conversion of the Note will be issued pursuant to the exemption from the registration requirements of the Securities Act provided by Section 4(a)(2) thereof, as a transaction not involving a public offering.”

IGC Pharma, Inc. entered into Securities Purchase Agreement and Promissory Note with Vanquish Funding Group Inc. valued at Aggregate principal amount of $238,050 (original issue discount of $31,050), purchase price $207,000 (effective 2026-04-14).

“In addition to it, IGC Pharma, Inc. (“IGC” or the “Company”) executed a Securities Purchase Agreement (the “Purchase Agreement”) with Vanquish Funding Group Inc., a Virginia corporation (“VFG” or the “Holder”). Pursuant to the terms of the Purchase Agreement, the Company issued a Promissory Note (the “Note”) to VFG with a total aggregate principal amount of $238,050, which includes an original issue discount of $31,050. The aggregate purchase price paid by VFG for the Note is $207,000. The Note matures on March 30, 2027 (the “Maturity Date”). The Company may prepay the Note in full at any time by providing VFG with prior written notice.”

IGC Pharma, Inc. entered into Securities Purchase Agreement and Promissory Note with FirstFire Global Opportunities Fund, LLC valued at Aggregate principal amount of $346,910 (original issue discount of $39,910), purchase price $307,000 (effective 2026-04-14).

“On April 10, 2026, IGC Pharma, Inc. (“IGC” or the “Company”) executed a Securities Purchase Agreement (the “Purchase Agreement”) with FirstFire Global Opportunities Fund, LLC, a Delaware limited liability company (the “FirstFire” or the “Holder”). The execution and delivery of the Purchase Agreement and the related Promissory Note were completed on April 14, 2026. Pursuant to the terms of the Purchase Agreement, the Company issued a Promissory Note (the “Note”) to FirstFire with a total aggregate principal amount of $346,910, which includes an original issue discount of $39,910. The aggregate purchase price paid by FirstFire for the Note is $307,000. The Note matures on April 10, 2027 (the “Maturity Date”). The Company may prepay the Note in full at any time by providing FirstFire with prior written notice.”

IGC Pharma, Inc. incurred convertible notes of $238,050 with Vanquish Funding Group Inc. at 12% maturing March 30, 2027.

“In addition to it, IGC Pharma, Inc. (“IGC” or the “Company”) executed a Securities Purchase Agreement (the “Purchase Agreement”) with Vanquish Funding Group Inc., a Virginia corporation (“VFG” or the “Holder”). Pursuant to the terms of the Purchase Agreement, the Company issued a Promissory Note (the “Note”) to VFG with a total aggregate principal amount of $238,050, which includes an original issue discount of $31,050. The aggregate purchase price paid by VFG for the Note is $207,000. The Note matures on March 30, 2027 (the “Maturity Date”). The Company may prepay the Note in full at any time by providing VFG with prior written notice. Solely upon the occurrence and continuation of an Event of Default under each of the Notes, each of VFG and FirstFire has the right, but not the obligation, to convert all or any portion of the outstanding balance of its respective Note — including principal, accrued interest, and any applicable default amounts — into shares (the “Conversion Shares”) of”

IGC Pharma, Inc. incurred convertible notes of $346,910 with FirstFire Global Opportunities Fund, LLC at 12% maturing April 10, 2027.

“On April 10, 2026, IGC Pharma, Inc. (“IGC” or the “Company”) executed a Securities Purchase Agreement (the “Purchase Agreement”) with FirstFire Global Opportunities Fund, LLC, a Delaware limited liability company (the “FirstFire” or the “Holder”). The execution and delivery of the Purchase Agreement and the related Promissory Note were completed on April 14, 2026. Pursuant to the terms of the Purchase Agreement, the Company issued a Promissory Note (the “Note”) to FirstFire with a total aggregate principal amount of $346,910, which includes an original issue discount of $39,910. The aggregate purchase price paid by FirstFire for the Note is $307,000. The Note matures on April 10, 2027 (the “Maturity Date”). The Company may prepay the Note in full at any time by providing FirstFire with prior written notice. In addition to it, IGC Pharma, Inc. (“IGC” or the “Company”) executed a Securities Purchase Agreement (the “Purchase Agreement”) with Vanquish Funding Group Inc., a Virginia corpora”

IGC Pharma, Inc. entered into a credit facility with One Deck Capital, Inc. valued at approximately $219,000.

“The Company entered into a loan agreement with One Deck Capital, Inc. (“One Deck”), pursuant to which the Company received approximately $219,000 in financing (the “One Deck Loan”).”

IGC Pharma, Inc. entered into Promissory Note with Vanquish Funding Group Inc. valued at $353,050 (effective 2026-03-05).

“Pursuant to the terms of the Purchase Agreement, the Company issued a Promissory Note (the “Note”) to VFG with a total principal amount of $353,050”

IGC Pharma, Inc. entered into Securities Purchase Agreement with Vanquish Funding Group Inc. (effective 2026-03-05).

“On March 5, 2026, IGC Pharma, Inc. (“IGC” or the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with Vanquish Funding Group Inc., a Virginia corporation (“VFG” or the “Holder”).”

IGC Pharma, Inc. incurred loan of approximately $219,000 with One Deck Capital, Inc..

“The Company entered into a loan agreement with One Deck Capital, Inc. (“One Deck”), pursuant to which the Company received approximately $219,000 in financing (the “One Deck Loan”).”

IGC Pharma, Inc. incurred loan of $353,050 with Vanquish Funding Group Inc. maturing February 28, 2027.

“On March 5, 2026, IGC Pharma, Inc. (“IGC” or the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with Vanquish Funding Group Inc.”

IGC Pharma, Inc. entered into 2025 Subscription Agreement with certain investors valued at approximately $234 thousand (effective 2026-01-05).

“entered into a Subscription Agreement (the “2025 Subscription Agreement”) with certain investors named therein (collectively, the “Investors”), pursuant to which the Company agreed to issue and sell to the Investors, in a registered direct offering (the “Offering”), an aggregate of 779,997 shares of the Company’s common stock”

IGC Pharma, Inc.: Changed fiscal year-end from March 31 to December 31 (effective 2025-12-31).

“the Board of Directors (the “Board”) of IGC Pharma, Inc. (the “Company”) approved a change in the Company’s fiscal year-end from March 31 to December 31. The fiscal year change will be effective on December 31, 2025.”

IGC Pharma, Inc.: Amended articles to increase authorized common stock from 150,000,000 to 600,000,000 shares (effective 2025-12-12).

“Effective December 12, 2025, IGC Pharma, Inc. (the “Company”) amended its Amended and Restated Articles of Incorporation in order to give effect to a previously announced increase of its authorized common stock from 150,000,000 shares to 600,000,000 shares.”

IGC Pharma, Inc. completed a disposition involving Wellness Essentials Northwest LLC for fair value of approximately $2.7 million (closed 2025-11-13).

“On November 13, 2025, the closing conditions were satisfied and the transactions under the Sale Agreement were consummated for a fair value of approximately $2.7 million.”

IGC Pharma, Inc. entered into 2024 Share Purchase Agreement with Bradbury Asset Management (Hong Kong) Limited valued at $3,000,000 (effective 2024-03-22).

“On March 22, 2024, IGC Pharma, Inc. (“IGC” or the “Company”) entered into the 2024 Share Purchase Agreement (the “2024 SPA”) with Bradbury Asset Management (Hong Kong) Limited (“Bradbury”) relating to the sale and issuance by our company to the investors of an aggregate of 8,823,529 shares of our common stock, for a total purchase price of $3,000,000”

IGC Pharma, Inc. entered into Sales Agreement with A.G.P./Alliance Global Partners valued at aggregate offering price subject to certain limitations on the amount of Common Stock that may be of (effective 2024-03-19).

“On March 19, 2024, IGC Pharma, Inc. (the “Company”) entered into a new Sales Agreement (the “Agreement”) with A.G.P./Alliance Global Partners (the “Agent”)”

Terry Lierman was appointed as independent Class B director at IGC Pharma, Inc..

“On March 12, 2024, the Board of Directors (the “Board”) of IGC Pharma, Inc. (the “Company” or “IGC”) appointed Mr. Terry Lierman (“Mr. Lierman”) to serve on the Board as a Class B director.”

IGC Pharma, Inc. entered into Sales Agreement with A.G.P./Alliance Global Partners valued at up to $60 million.

“IGC Pharma, Inc. (the “Company”) entered into a Sales Agreement (the “Agreement”) with A.G.P./Alliance Global Partners (the “Agent”)”

IGC Pharma, Inc. shareholders approved Advisory vote on frequency of say-on-pay votes (every three years) at the 2023-08-18 meeting.

“5. Approval to, by a non-binding advisory vote, setting the frequency of say-on-pay votes at future annual meetings of stockholders to every three years; 1 YEAR 2 YEARS 3 YEARS Abstain Broker Non-votes 2,429,382 181,013 13,078,308 479,811 11,035,662”

IGC Pharma, Inc. shareholders approved Advisory approval of compensation of named executive officers at the 2023-08-18 meeting.

“4. Approval of a non-binding advisory resolution to approve the compensation of the Company’s named executive officers. For Against Abstain Broker Non-votes 15,339,051 769,054 60,409 11,035,662”

IGC Pharma, Inc. shareholders approved Approve grant of 3,000,000 shares of common stock to employees, advisors, directors, and consultants at the 2023-08-18 meeting.

“For Against Abstain Broker Non-votes 14,268,013 1,861,386 39,115 11,035,662”

IGC Pharma, Inc. shareholders approved Ratify appointment of Manohar Chowdhry & Associates as independent registered public accounting firm for 2024 at the 2023-08-18 meeting.

“2. Proposal to ratify the appointment of Manohar Chowdhry & Associates as the Company’s independent registered public accounting firm for the 2024 fiscal year. For Against Abstain 26,949,467 163,043 91,666”

IGC Pharma, Inc. shareholders approved Election of Director Claudia Grimaldi at the 2023-08-18 meeting.

“1. Election of Directors. Nominee For Withhold Broker Non-votes Claudia Grimaldi 14,740,248 1,428,266 11,035,662”

IGC Pharma, Inc. incurred credit facility of up to USD$12,000,000.00 with O-Bank, CO., LTD. at interest rate mentioned in the Certificate of Deposit, as the case may be, plus maturing first anniversary of the Effective Date.

“On June 30, 2023, (the “Effective Date”), IGC Pharma, Inc. (“IGC” or “Borrower”) entered into a Master Loan and Security Agreement along with the General Banking Facility Letter (collectively called the “Loan Agreement”) with O-Bank, CO., LTD., a banking corporation incorporated under the laws of Taiwan, as administrative agent and lender (the “Lender’) pursuant to which the Borrower may borrow up to USD$12,000,000.00 only or the equivalent thereof in other major currencies (the “Credit Facility”).”

IGC Pharma, Inc. entered into Loan Agreement with O-Bank, CO., LTD. valued at up to USD$12,000,000.00 (effective 2023-06-30).

“On June 30, 2023, (the “Effective Date”), IGC Pharma, Inc. (“IGC” or “Borrower”) entered into a Master Loan and Security Agreement along with the General Banking Facility Letter (collectively called the “Loan Agreement”) with O-Bank, CO., LTD., a banking corporation incorporated under the laws of Taiwan, as administrative agent and lender (the “Lender’) pursuant to which the Borrower may borrow up to USD$12,000,000.00 only or the equivalent thereof in other major currencies (the “Credit Facility”).”

IGC Pharma, Inc. entered into 2023 Share Purchase Agreement with certain investors valued at $3,000,000 (effective 2023-06-30).

“On June 30, 2023, IGC Pharma, Inc. (“IGC” or the “Company”) entered into the 2023 Share Purchase Agreement (the “2023 SPA”) with certain investors relating to the sale and issuance by our company to the investors of an aggregate of 10,000,000 shares of our common stock, for a total purchase price of $3,000,000 or $0.30 per share, subject to the terms and subject to the conditions set forth in the Purchase Agreement.”

IGC Pharma, Inc.: Amended Amended and Restated Bylaws solely to reflect the name change (effective 2023-03-07).

“In addition, the Company adopted an Amendment to its Amended and Restated Bylaws, (the “Bylaw Amendment”), effective March 7, 2023, solely to reflect the name change.”

IGC Pharma, Inc.: Company changed name from India Globalization Capital Inc. to IGC Pharma, Inc. via Articles of Amendment to Amended and Restated Articles of Incorporation (effective 2023-03-30).

“Effective March 30, 2023, India Globalization Capital Inc., a Maryland corporation (the “we,” “our,” “us” or the “Company”), changed its name to “IGC Pharma, Inc.” by filing Articles of Amendment to the Company’s Amended and Restated Articles of Incorporation with the State Department of Assessments and Taxation of Maryland on March 7, 2023 (the “Charter Amendment”).”

John E. Lynch departed as Director at IGC Pharma, Inc..

“On December 24, 2022, John E. Lynch, a Director of India Globalization Capital Inc. (the “Company” or “IGC”), passed away.”

Claudia Grimaldi was elected as Class A Director at IGC Pharma, Inc..

“and Ms. Claudia Grimaldi was elected to the Company’s Board of Directors at the Annual Meeting, to serve as a Class A director, until the 2023 annual meeting of stockholders”

James Moran was elected as Class C Director at IGC Pharma, Inc..

“On September 9, 2022, Ram Mukunda and Congressman James Moran were elected to India Globalization Capital’s (the “Company”) Board of Directors at the 2022 Annual Meeting of Stockholders (the “Annual Meeting”), to serve as Class C directors, until the 2025 annual meeting of stockholders”

Ram Mukunda was elected as Class C Director at IGC Pharma, Inc..

“On September 9, 2022, Ram Mukunda and Congressman James Moran were elected to India Globalization Capital’s (the “Company”) Board of Directors at the 2022 Annual Meeting of Stockholders (the “Annual Meeting”), to serve as Class C directors, until the 2025 annual meeting of stockholders”

Claudia Grimaldi was appointed as Director at IGC Pharma, Inc..

“On March 23, 2022, the Board of Directors (the “Board”) of India Globalization Capital Inc. (the “Company” “IGC” or “we”) appointed Ms. Claudia Grimaldi (“Ms. Grimaldi”) to serve on the Board as a non-independent director.”

Jim Moran was appointed as Class C director at IGC Pharma, Inc..

“On January 18, 2022, the Board of Directors (the “Board”) of India Globalization Capital Inc. (the “Company” or “IGC”) appointed former Congressman Jim Moran (“Congressman Moran”) to serve on the Board as a Class C director.”

Richard Prins was elected as Class B director at IGC Pharma, Inc..

“On October 15, 2021, Richard Prins was elected to India Globalization Capital’s (the “Company”) Board of Directors at the Annual Meeting, to serve as a Class B director”